COMPASS Pathways plc Investor Event Transcript, Nov 18, 2026
COMPASS Pathways plc (CMPS)
Compass Pathways has completed its FDA filing for COMP360, its synthetic psilocybin for treatment-resistant depression, supported by two Phase III studies enrolling close to 900 patients. It expects to be launch ready by the end of the year and to launch in the first half of next year, subject to approval. Management said about 93% of the population lives in states that will reschedule within 30 days. AI summary
Conference Transcript - CMPS 2026-11-18
Andrew Tsai, Analyst — Jefferies
Welcome. Hi, everyone. I'm Andrew Tsai, Senior Biotech Analyst at Jefferies. Thanks for joining me today, and it's my pleasure to have the Compass Pathways team with me. To my direct right is Kabir Nath, CEO. To his right is Laurie Engelbert, Chief Commercial Officer, and to Laurie's right is Terry Loxam, CFO. Welcome, all of you. Yeah, to help level set our discussion today, would you guys mind talking about the COMPAS story, what stage you're at, what you're trying to achieve? Milestones could be helpful, too.
Kabir Nath, CEO
Great. No, thanks, Andrew, and I'll do that as quickly as I can. So we're very excited that COMPAS has recently completed our filing of COMP360 to the FDA. So we have completed a very large, very robust set of studies for Comp360, our proprietary synthetic form of psilocybin, for treatment-resistant depression. Two Phase III studies, enrolling close to 900 patients between them, highly statistically significant positive results, supported by a very robust Phase IIb. We have, as I said, completed our filing. We have a national priority voucher, which means that we can expect potentially a very rapid approval. And so we have been clearly guiding for some time that we will be ready to launch at the end of the year and expecting a launch in the first half of next year subject to approval. We'll obviously talk a lot more about COM360, but why is this a transformational moment for psychiatry? Because in terms of rapidity of onset, durability of effect from very limited dosing, this is unlike anything that has ever been seen in depression and potentially represents a transformative new option, a new paradigm for patients, providers, and indeed for the field of psychiatry. So just a couple of small milestones coming up, Andrew.
Andrew Tsai, Analyst — Jefferies
Fingers crossed on everything, yes. And so you just mentioned that, you know, why... Comp 360 is quite differentiated, but to hone in on things, Spravato, that's on track to do 5 billion. Peak cells also in TRD. You spoke to durability and infrequent dosing, so can you just tell us what is Spravato's dosing paradigm, how does that compare to yours?
Lori Englebert, Other
Thanks, Andrew. That peak sales number for Spravato just keeps going up and up every single conference we go to, and we do believe they will hit 5 billion as well, so we have no reason to believe that they want. Right now, it's probably important to set the stage for what a TRD patient population looks like. There are about 4 million Americans right now who are considered treatment-resistant depression or depressed, and what I want to point out is that Spravato is only treating 100,000 of those, and they will do $2 billion this year plus. So in order for them to get to their 4 billion, 5 billion peak sales that they are projected to get to, you can estimate that they will only treat about 250,000 patients out of 4 million. That's a very small piece of the TRD pie. So it is important also to note that Spravato is the only approved product in treatment-resistant depression. In fact, many of the MDD products that are approved right now have tried to prove efficacy in this patient population and have failed. Therefore, the population of patients that we studied at our clinical trial and the efficacy that we showed really will be very important for patients, providers, and payers when we get approval.
Andrew Tsai, Analyst — Jefferies
And what's unique in this situation is Spravato's built this nice infrastructure that I think you guys plan to leverage. So maybe talk about the push and pulls of how you plan to leverage that infrastructure.
Lori Englebert, Other
Yeah, happy to. I also will mention why we believe Comp360 will do better than Spravato in the long run. So when Spravato launched seven years ago, they launched into an environment which had about, let's call it, less than 20 sites that could actually administer the product. And that is because the requirements needed to administer a multi-hour treatment was rather new in psychiatry for a pharmacologic product. Some sites have been doing TMS, ECT, but very small patient numbers were associated with that. So when Spravato came to market, the infrastructure built to administer these multi-hour treatments was very small. Fast forward to today, they are growing at about 500 sites a quarter, and right now they're about 8,500. So by the time we launch, we expect that to be about 9,000 sites or more that will be able to administer multi-hour treatments like Comp360. The reason we believe Comp360 is and will become more valuable than Spravato is the fact that Comp360 only requires somewhere between two and four doses on an annualized basis. You compare and contrast that to Spravato, they are somewhere between 35 and 55 doses on an annualized basis. This is not trivial because this speaks to patient burden. Patients have to take days off work to go in and get Spravato treatment. They are three-hour appointments at minimum, and you cannot go back to work afterwards. And also, you have to be driven from those appointments. So not only is it a burden for the patients, but it's also a burden for the caregivers. It's part of the reason why the uptake has not been so great for Spravato is because the patient burden is quite immense. You have a product like Comp360 with fairly comparable efficacy and tolerability to Spravato, and you offer it to patients in which you only need treatment two to four times a year. This is transformational for patients as well as the sites.
Terry Loxam, CFO
And it's probably worth just adding on there, from an infrastructure perspective, the infrastructure that Spravato is leveraging is the same as what Comp360 will use. There's no change in the rooms needed or in the personnel that is administering Comp360 versus Spravato. So it's ready-made, and we can go right into that infrastructure.
Lori Englebert, Other
And they have capacity. So keep building off each other. They have capacity. That is also something that is somewhat of a misnomer right now is that they're all operating at capacity, and we'll need to build out capacity for these psychedelics. I can tell you right now, on average, if you take the 8,500, they're seeing one Spravato patient a day. That's on average. Obviously, it's concentrated at higher ends and longer tails, but that is the average. There's plenty of capacity. We also know all of the sites, and they are more than willing to build out capacity if needed. to facilitate these additional treatments coming to market.
Andrew Tsai, Analyst — Jefferies
Super helpful, thank you. And so maybe let's talk about the interim, is that you finished filing your NDA, I think November 9th was the date. You have this CMPV voucher. I just wanted to make sure that still stands because FDA, I think, is taking away CMPVs.
Kabir Nath, CEO
Yeah, so just to remind people that even before the MPV, we'd actually agreed on a rolling submission and review with the agency before we were awarded the MPV. So what I can tell you is that that process has absolutely been taking place. The submission clearly, as we said last week, we had completed the submission, but that really was completing after a number of modules had gone in. We know that the agency has been reviewing those. It's been an incredibly interactive six, seven months with the agency. We see no reason to suggest that they're slowing down or backtracking on their commitment to try and get this done within the one to two months from us completing our submission. So, yes, there was some public news. The reality is there have been no new MPVs actually issued since McCary left, so it's clear the program was winding down from the point of view of new MPVs. The company's been covered, but from our perspective, we have no reason to believe they're not going to try to live up to the commitment.
Andrew Tsai, Analyst — Jefferies
And so, if we added one to two months from November 9th, this could be December 9th to January 9th?
Kabir Nath, CEO
So, we have said consistently we will be launch ready by the end of the year because, you know, if necessary, that's right. That said, there is then the question of rescheduling, which I don't know if maybe Laurie wants to address.
Lori Englebert, Other
I'm happy to take that, Andrew, if you want me to go there with the timelines. So we have committed to and are and will be launch ready by the end of the year, regardless of what happens. And the reason we have to do that is because there is fluidity in terms of timing, mostly due to not only the CNPV, as well as the executive order that came in April in terms of encouraging the DEA to reschedule psychedelics in a much faster fashion than the 90 days they typically take. Um, we have no insight into if they will do that. Um, I would assume as a consumer of medication, medications, you do not want manufacturers interfering with the DEA scheduling decisions. So they refuse to speak to manufacturers. Um, and so we, we have other tentacles where we are trying to be able to understand if they expect earlier timing, but for now it is somewhere between FDA approval and 90 days in which the DEA will reschedule. However, It is also important to note that once you get DEA rescheduling, you still need one more step before you can actually prescribe the product legally, and we can ship the product legally, and consumers can consume it legally, and that is to have the states reschedule. And so there is a lot of work that's ongoing and has been done to make sure that states reschedule in a timely manner, and right now we're sitting with about 93% of the population that will reschedule within 30 days. I also want to mention that it does not mean that the other states that have not committed to a timely rescheduling won't. It just means that legally they're not bound by it.
Andrew Tsai, Analyst — Jefferies
Makes sense. And what kind of DEA scheduling do you think you'll get? And hypothetically, even if you got a Schedule II, does that matter in terms of uptake?
Lori Englebert, Other
So right now, we're anticipating that the schedule will be Schedule 3, which is consistent with Spravato right now. Even in an instance which there is no evidence to support that we were given a Schedule 2 that would not make a difference based on the way that this product, given that it is a scheduled product and also a product that is administered in front of an HCP, it is not something that a patient takes home. There is no difference in terms of requirements for the Schedule 2. Remember, these are psychiatrists that will be prescribing this product most likely because of the interventional psychiatry infrastructure, and almost all ADHD drugs are Schedule II, so they are very used to handling Schedule II products, even ones that go home with patients.
Andrew Tsai, Analyst — Jefferies
Okay. And actually, I forgot to ask during the FDA review process, when I looked at the NPV comps, precedents, I felt like the FDA assigned a PDUFA date two weeks after the submission. Here, we're possibly in the second. I don't remember my date, so we can expect a PDUFA date soon in your review?
Kabir Nath, CEO
Yeah, we don't know. I mean, I think, yeah, we do expect an acceptance with a PDUFA. You are right. We think that will happen. It may well be that the PDUFA is a standard six-month priority review because we have breakthrough, so we would expect a priority review that the agency will then beat. So, again, the MPV precedents are a little bit all over the place, but some of them do suggest a standard PDUFA that then the agency takes pride in beating by a matter of months. I see.
Andrew Tsai, Analyst — Jefferies
Thank you. And you've received, quote-unquote, soft confirmation from the FDA, no adcom. That's still the expectation.
Kabir Nath, CEO
Again, ultimately, it is an FDA decision. We think it unlikely, but we don't have formal confirmation, and we will be ready for one. I mean, again, we designed our studies in such a way that we truly... We attempted and did address some of the key issues, such as unblinding and the role of support and so on, but we would be ready for one if there was to be.
Andrew Tsai, Analyst — Jefferies
Yes, of course. And this NDA was a rolling NDA, so you were able to submit modules and a lot of it for many months now. And as I think about CMC manufacturing, number one, how prepared are you guys so far? Secondly, has the FDA visited your site for inspections?
Kabir Nath, CEO
So, completely prepared from a manufacturing perspective, that is an area we have zero concerns around. Both our drug substance and drug product are sites that have been inspected multiple times in the past. That process is underway. What I can tell you from an inspection perspective is from a clinical site, CRO and so on, all that is done, and that was done relatively early in the process from the FDA's perspective.
Andrew Tsai, Analyst — Jefferies
And once Comp360 is approved, I think the expectation is there will be a REMS similar to Spravato. That said, how comparable or different do you expect that REMS to be compared to Spravato?
Lori Englebert, Other
Yeah, so I want to point you to a couple of things that we're basing our assumptions on. So, again, we don't have a finalized REMS, so all of this is premature until that final REMS comes through. But I can give you the logic and the basis on our thinking. The FDA themselves have guided us to look at the Spravato REMS as guidance in terms of our starting place for our own REMS. They also guided us to look at the Lycos ADCOM back from a couple of years ago and the draft guidance that they gave for REMS for them, which is very consistent with the Spravato REMS, so no difference there in terms of expectations. We expect, and Terry made a point that was very important for people to understand, is that we do not expect the sites that exist today. Again, there are 8,500 of them, growing 500 a quarter, so growing very rapidly. We do not expect them to need or require any different personnel, resources, room configurations. Nothing like that will be dictated that will be different from a Spravato standpoint in the REMS.
Andrew Tsai, Analyst — Jefferies
Mm-hmm. And currently, Spravato's REMS reads, what does it specify in terms of who is monitoring the patient? Just remind us what that REMS is.
Lori Englebert, Other
Yeah, it's fairly simple language. It just says that the patient needs to be monitored for two hours after administration by a health care provider. Now, what is important to understand is that does not say, does that person need to be in the room? Is it CCTV? That is up to clinical practice and the way that clinical medicine is practiced. So the sites, some will have someone sitting in the room. Some will monitor by CCTV. It depends on how familiar they are with the clinical experience of patients with Spravato, and we would expect there to be similar behavior with Comp360.
Andrew Tsai, Analyst — Jefferies
Very cool. Thanks. And on pricing, remind us how Spravato is priced on an annual basis. Is there a chance, because if you believe your product is superior, there's pricing power here?
Lori Englebert, Other
Yeah, there absolutely is pricing power here. And Spravato right now, because they have two doses and they have different maintenance treatment frequency in their label, is somewhere between $50,000 and $65,000 on an annualized basis. The way that we have conducted all of our market research with payers, which is important to note, We've done fairly extensive market research with payers. We did that intentionally because this dosing paradigm that Comp360 will have is very different than anything payers have covered before. So we wanted to make sure we really understood the dynamics with payers, and we have very strong confidence that we can and should price at a premium to Spravato on an annualized basis.
Andrew Tsai, Analyst — Jefferies
Okay. Thank you. And going to the launch then, possibly in Q2 or first half, I think first half. So, how many sales reps have you planned for, if the target is the existing centers, do you need that many, is the root of the question.
Lori Englebert, Other
Yeah, so we've been pretty strategic in the way that we're thinking about how we're going to deploy the sales force. So, again, 8,500 sites. Typical rule of thumb is about 100 HGPs to one sales rep. That's just general practice. And so you would think we wouldn't need that many. We are actually going to deploy about 100. And the reason is because, one, this growth is going very fast, as well as the fact that we need to make sure that we are covering potential referring psychiatrists Psychiatrist or referring physicians that can feed patients into these interventional treatment centers. It's important to note, though, the sales reps will not be the only field force that we have out in the field. And we did, again, we did this pretty strategically, knowing that reimbursement is going to be such an important factor in sites, you know, willingness to prescribe, prescribe again, making sure that they can get reimbursed for the six-hour monitoring time. We're going to have a very robust field reimbursement team, and then all the other ancillary field teams like MSLs, thought leader liaisons, key account managers.
Andrew Tsai, Analyst — Jefferies
Great. And on the payer front, there's two dynamics to think about, I guess, the drug reimbursement as well as the staff monitoring at the sites to incentivize the sites to deliver this therapy. Can you talk about how the payer access will work initially and over time?
Lori Englebert, Other
Yeah, absolutely. So I'll cover the drug one first because, ironically enough, that's the easiest one to talk about. And the drug reimbursement one will be just like any other new product launching in the U.S., and that is it will likely go under an NDC block by these payers because the payers will need time to do their assessment to understand the value that the product is bringing to the health care system. That is all normal. That happens with every product launch, especially one that's coming in a new class. So in order to be prepared for that, we've instilled a very robust patient support program, patient affordability program, where cost of the drug itself is not a burden for patients if the product is not covered on their insurance or on formulary access just yet. It is important to note, though, we have been discussing and engaging with payers for quite some time now, for well over six months, And those discussions are going remarkably well for the first time in my career, and I've been doing this a very long time. It is a pull from the payers, not a push from the manufacturers to actually have these engagements with payers. So that is very encouraging in terms of them really understanding the value that the data that we've generated in treatment-resistant depression brings. The more complicated piece is the reimbursement piece, and it's only complicated because people believe it's complicated. And also because it was one of the major deterrents for Spravato when they launched. They didn't understand the reimbursement time. Again, this was one of the first pharmacologic products to launch that needed monitoring time more than just going to your retail pharmacy and picking up a prescription. And so reimbursement as providers launch was part of their stumbling blocks coming out of the gate. We've obviously learned a lot. They've learned a lot. Obviously, they're doing quite well. We've learned a lot from what they did. And what our objective is at launch is to make sure that we are not disadvantaged versus the hourly rate that Spravato is getting right now. There are two points to make about our reimbursement time period. One is that Spravato right now uses general evaluation and management codes. So it is, unfortunately, quite complex to attach a lot of codes to get reimbursement, but they're used to it. We have and worked on getting what's called CPT3 codes, which means that they are support and monitoring codes that were put into the exploratory form because payers haven't yet valued the hourly rate for monitoring psychedelics. Since we will be first to market, we will need time to generate the demand for this. So the CPT3 codes need to be demonstrated to payers that there's need for it, and then it will progress and be valued at a CPT1 code. We expect that to take about 12 to 18 months, but it's important. The most important thing to note is that it will not be disadvantaged as Roboto at launch.
Andrew Tsai, Analyst — Jefferies
Very clear.
Kabir Nath, CEO
And just to build on that, Andrew, I think it's really important as we talk about the potential here and so on, And one of the factors that are driving this is this growth of psychiatry as a business. So as we're very well aware, many other specialties have become businesses, oncology, rheumatology, immunology, with buy-and-bill driving that. For the first times, Provado offered that to psychiatry. You now see around 30, 35 percent of that volume is buy-and-bill. We would expect, with our potential launch and other psychedelics coming behind us, to see a very rapid increase in that buy-and-bill opportunity. And we've seen that in terms of who's actually funding this from PE money and so on moving in on the infrastructure side of psychiatry. So that, again, is a really important long-term reason that underpins our belief in the potential here and the opportunity.
Terry Loxam, CFO
And just one more point to add. While the CPT-3 codes are getting evaluated in that 12 to 18-month period, the providers will be able to get reimbursed using the general evaluation and management codes. So when Lori says there won't be disadvantage, it's because they're going to be able to use the same codes they're using for Spravato, for Comp360, just adding more increments for the time above the two hours that they're using for Spravato. So they still will be able to get that reimbursement. They'll just get more reimbursement, we believe, once the CBT3 codes are valued.
Andrew Tsai, Analyst — Jefferies
I see. And I think you've mentioned how you'll share KPIs along the way, remind us what they are, and then secondly, are IMS Symphony scripts trackable?
Lori Englebert, Other
So I'll answer the latter one first. Yes, they are trackable. We've done extensive work to make sure that our specialty pharmacies are reporting to our QVS Symphony, all the major reporting outlets. They will have the traditional capture rates or maybe slightly modified, but they all will be viewable. It's an important question to answer, Andrew, because... Um, one of the things, uh, for consideration is, um, when we launch, um, this is not a retail drug, um, that is traditionally, you know, antidepressants. You start looking at how fast those scripts are popping in week one that shows and demonstrates demand. That is not the environment that we're operating in, and we are taking extraordinary care to make sure that the sites are well-prepared, that patients are well-prepared for the experience that they're about to go through, Because one bad experience is going to have a pretty massive trickle-down effect. And so that's why we're putting so much effort into reimbursement support, into making sure that the sites are supported from scientific exchange with MSLs, really understanding this. And so the way that we expect it to happen is, obviously, if a site has a really good experience, of which they will write the prescription, they have a good experience, they're going to tell their colleagues, they're going to want to write again. So the KPIs that are important for us to watch will be, obviously, NBRXs. Also, the infrequency of dosing here makes TRXs a little bit hard to monitor in the early months. So MBRX will be the primary driver, new prescribers, and obviously patients.
Andrew Tsai, Analyst — Jefferies
Thanks. And REMS.
Lori Englebert, Other
And REMS certification. That will probably be the first one and the first KPI that we worked on.
Andrew Tsai, Analyst — Jefferies
I see. Okay, perfect. And then in the last couple minutes, I did want to ask on USONA, who actually filed their psilocybin compound before you. So can you reassure us why that will not be a potential issue, especially I think investors think the worst case scenario of a low price, for instance.
Kabir Nath, CEO
Yeah, and just before Laurie gets to that, just to be clear, you certainly have not confirmed that they filed. There has been a report that they have, and under normal circumstances of a single trial in MDD for which no data has been reported, this would not be approvable, but we do understand these are not normal circumstances. We also believe that they infringe, so if they were ever to get to an approval, we would take appropriate measures.
Lori Englebert, Other
It's also worth noting that they are only blinded out to six weeks, and the FDA just released guidance in July, so very, very recently, that they expect, and their direction for clinical trials is to blind at least out to 12 weeks. So not only are they only producing one trial, they are also not meeting the guidelines that the FDA just put out back in July. Regardless, as Kabir said, we do realize these are unprecedented times and uncertainty around that. I want to point out they are MDD and we are TRD, one that is a very different patient population in terms of which to discuss with payers. Also, I think it's probably worth noting that there is a very distinct science behind pricing because you have to feed everyone in the chain along the way, 3PLs, distributors. Pharmacies, all of them are taking a cut, so you have to price at a certain level. Also, from the buy and bill standpoint, you have to price at a certain level to make it attractive for everyone in the value chain. The chances of them coming in with a very low-priced product, it makes it very hard. Into the commercial channel. Into the commercial channel. It makes it very hard to see.
Andrew Tsai, Analyst — Jefferies
Okay, perfect. Thank you so much for the updates. Congrats on the progress. Good luck on everything. Thanks very much, everyone.